{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T20:48:14Z","timestamp":1789591694908,"version":"build-2803163510"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100017962","name":"Jiangsu Commission of Health","doi-asserted-by":"crossref","award":["LKM2023011"],"award-info":[{"award-number":["LKM2023011"]}],"id":[{"id":"10.13039\/100017962","id-type":"DOI","asserted-by":"crossref"}]},{"name":"The Project for the Construction of \u201cFlagship\u201d Departments of Integrated Traditional Chinese and Western Medicine","award":["[2024]221"],"award-info":[{"award-number":["[2024]221"]}]},{"name":"The Project for the Construction of \u201cFlagship\u201d Departments of Integrated Traditional Chinese and Western Medicine","award":["[2024]221"],"award-info":[{"award-number":["[2024]221"]}]},{"name":"The Project for the Construction of \u201cFlagship\u201d Departments of Integrated Traditional Chinese and Western Medicine","award":["[2024]221"],"award-info":[{"award-number":["[2024]221"]}]},{"name":"Nanjing famous Chinese medicine studio construction project","award":["[2023]9"],"award-info":[{"award-number":["[2023]9"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-24027-2","type":"journal-article","created":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T21:19:14Z","timestamp":1763414354000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Synergistic anticancer effects of carrier-free self-assembled doxorubicin and emodin nanoparticles in non-small cell lung cancer"],"prefix":"10.1038","volume":"15","author":[{"given":"Cheng","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangyang","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoli","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingling","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelei","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhang","family":"Nan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaoyao","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaojuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,17]]},"reference":[{"issue":"12","key":"24027_CR1","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1001\/jamaoncol.2021.4932","volume":"7","author":"AK Ganti","year":"2021","unstructured":"Ganti, A. K., Klein, A. B., Cotarla, I., Seal, B. & Chou, E. Update of Incidence, Prevalence, Survival, and initial treatment in patients with Non-Small cell lung cancer in the US. JAMA Oncol. 7(12), 1824\u20131832 (2021).","journal-title":"JAMA Oncol."},{"issue":"10","key":"24027_CR2","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1002\/cac2.12359","volume":"42","author":"P Chen","year":"2022","unstructured":"Chen, P., Liu, Y., Wen, Y. & Zhou, C. Non-small cell lung cancer in China. Cancer Commun. (London England). 42(10), 937\u2013970 (2022).","journal-title":"Cancer Commun. (London England)"},{"issue":"4","key":"24027_CR3","doi-asserted-by":"publisher","first-page":"249","DOI":"10.6004\/jnccn.2204.0023","volume":"22","author":"GJ Riely","year":"2024","unstructured":"Riely, G. J. et al. Non-Small cell lung Cancer, version 4.2024, NCCN clinical practice guidelines in oncology. J. Natl. Compr. Cancer Network: JNCCN. 22(4), 249\u2013274 (2024).","journal-title":"J. Natl. Compr. Cancer Network: JNCCN"},{"issue":"1","key":"24027_CR4","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1158\/0008-5472.CAN-13-2620","volume":"74","author":"DH Shin","year":"2014","unstructured":"Shin, D. H., Choi, Y. J. & Park, J. W. SIRT1 and AMPK mediate hypoxia-induced resistance of non-small cell lung cancers to cisplatin and doxorubicin. Cancer Res. 74(1), 298\u2013308 (2014).","journal-title":"Cancer Res."},{"key":"24027_CR5","doi-asserted-by":"publisher","first-page":"113836","DOI":"10.1016\/j.ejmech.2021.113836","volume":"226","author":"S Mozaffari","year":"2021","unstructured":"Mozaffari, S. et al. Design and application of hybrid cyclic-linear peptide-doxorubicin conjugates as a strategy to overcome doxorubicin resistance and toxicity. Eur. J. Med. Chem. 226, 113836 (2021).","journal-title":"Eur. J. Med. Chem."},{"issue":"20","key":"24027_CR6","doi-asserted-by":"publisher","first-page":"7981","DOI":"10.1158\/0008-5472.CAN-10-0111","volume":"70","author":"YJ Mi","year":"2010","unstructured":"Mi, Y. J. et al. Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters. Cancer Res. 70(20), 7981\u20137991 (2010).","journal-title":"Cancer Res."},{"issue":"9","key":"24027_CR7","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1016\/j.ejca.2010.02.043","volume":"46","author":"L Guo","year":"2010","unstructured":"Guo, L. et al. Gene expression profiling of drug-resistant small cell lung cancer cells by combining MicroRNA and cDNA expression analysis. Eur. J. Cancer (Oxford England: 1990). 46(9), 1692\u20131702 (2010).","journal-title":"Eur. J. Cancer (Oxford England: 1990)"},{"issue":"3","key":"24027_CR8","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.lungcan.2014.03.015","volume":"84","author":"C M\u00f6rth","year":"2014","unstructured":"M\u00f6rth, C. & Valachis, A. Single-agent versus combination chemotherapy as first-line treatment for patients with advanced non-small cell lung cancer and performance status 2: a literature-based meta-analysis of randomized studies. Lung Cancer (Amsterdam Netherlands). 84(3), 209\u2013214 (2014).","journal-title":"Lung Cancer (Amsterdam Netherlands)"},{"issue":"1","key":"24027_CR9","doi-asserted-by":"publisher","first-page":"7449","DOI":"10.1038\/ncomms8449","volume":"6","author":"C Shi","year":"2015","unstructured":"Shi, C. et al. A drug-specific nanocarrier design for efficient anticancer therapy. Nat. Commun. 6(1), 7449 (2015).","journal-title":"Nat. Commun."},{"key":"24027_CR10","doi-asserted-by":"publisher","first-page":"5757","DOI":"10.2147\/IJN.S118568","volume":"11","author":"Y Gu","year":"2016","unstructured":"Gu, Y. et al. Nanomicelles loaded with doxorubicin and Curcumin for alleviating multidrug resistance in lung cancer. Int. J. Nanomed. 11, 5757\u20135770 (2016).","journal-title":"Int. J. Nanomed."},{"issue":"33","key":"24027_CR11","doi-asserted-by":"publisher","first-page":"36882","DOI":"10.1021\/acsami.0c09110","volume":"12","author":"YX Zhu","year":"2020","unstructured":"Zhu, Y. X. et al. Photosensitizer-Doped and plasma Membrane-Responsive liposomes for nuclear drug delivery and multidrug resistance reversal. ACS Appl. Mater. Interfaces. 12(33), 36882\u201336894 (2020).","journal-title":"ACS Appl. Mater. Interfaces"},{"issue":"1","key":"24027_CR12","doi-asserted-by":"publisher","first-page":"87","DOI":"10.32604\/CHD.2022.018452","volume":"17","author":"L Wang","year":"2022","unstructured":"Wang, L. et al. Assessment of reversibility in pulmonary hypertension related to congenital heart disease by using biomarkers and clinical features. Congenit. Heart. Dis. 17(1), 87\u201397 (2022).","journal-title":"Congenit. Heart. Dis."},{"issue":"Pt 2","key":"24027_CR13","doi-asserted-by":"publisher","first-page":"130915","DOI":"10.1016\/j.ijbiomac.2024.130915","volume":"267","author":"J Cao","year":"2024","unstructured":"Cao, J., Zhu, C., Cao, Z. & Ke, X. CPPs-modified Chitosan as permeability-enhancing chemotherapeutic combined with gene therapy nanosystem by thermosensitive hydrogel for the treatment of osteosarcoma. Int. J. Biol. Macromol. 267(Pt 2), 130915 (2024).","journal-title":"Int. J. Biol. Macromol."},{"issue":"30","key":"24027_CR14","doi-asserted-by":"publisher","first-page":"305602","DOI":"10.1088\/1361-6528\/aac0d3","volume":"29","author":"S Gatti","year":"2018","unstructured":"Gatti, S. et al. Hydrazone linked doxorubicin-PLA prodrug nanoparticles with high drug loading. Nanotechnology 29(30), 305602 (2018).","journal-title":"Nanotechnology"},{"issue":"3","key":"24027_CR15","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1021\/bm301999c","volume":"14","author":"Q Yin","year":"2013","unstructured":"Yin, Q. et al. Drug-initiated ring-opening polymerization of O-carboxyanhydrides for the Preparation of anticancer drug-poly(O-carboxyanhydride) nanoconjugates. Biomacromolecules 14(3), 920\u2013929 (2013).","journal-title":"Biomacromolecules"},{"key":"24027_CR16","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jconrel.2016.07.022","volume":"238","author":"B Zhang","year":"2016","unstructured":"Zhang, B. et al. Development and evaluation of oxaliplatin and Irinotecan co-loaded liposomes for enhanced colorectal cancer therapy. J. Controll. Release 238, 10\u201321 (2016).","journal-title":"J. Controlled Release: Official J. Controlled Release Soc."},{"key":"24027_CR17","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.addr.2019.06.008","volume":"143","author":"C Su","year":"2019","unstructured":"Su, C. et al. Absorption, distribution, metabolism and excretion of the biomaterials used in nanocarrier drug delivery systems. Adv. Drug Deliv. Rev. 143, 97\u2013114 (2019).","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"19","key":"24027_CR18","doi-asserted-by":"publisher","first-page":"11147","DOI":"10.1021\/acs.chemrev.5b00116","volume":"115","author":"Y Min","year":"2015","unstructured":"Min, Y., Caster, J. M., Eblan, M. J. & Wang, A. Z. Clinical translation of nanomedicine. Chem. Rev. 115(19), 11147\u201311190 (2015).","journal-title":"Chem. Rev."},{"key":"24027_CR19","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.bioactmat.2021.06.035","volume":"8","author":"H Mei","year":"2022","unstructured":"Mei, H. et al. Carrier-free nanodrugs with efficient drug delivery and release for cancer therapy: from intrinsic physicochemical properties to external modification. Bioactive Mater. 8, 220\u2013240 (2022).","journal-title":"Bioactive Mater."},{"key":"24027_CR20","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.jconrel.2018.11.032","volume":"294","author":"MK Shim","year":"2019","unstructured":"Shim, M. K. et al. Carrier-free nanoparticles of cathepsin B-cleavable peptide-conjugated doxorubicin prodrug for cancer targeting therapy. J. Controlled Release. 294, 376\u2013389 (2019).","journal-title":"J. Controlled Release"},{"key":"24027_CR21","doi-asserted-by":"publisher","first-page":"120347","DOI":"10.1016\/j.biomaterials.2020.120347","volume":"261","author":"MK Shim","year":"2020","unstructured":"Shim, M. K. et al. Cancer-specific drug-drug nanoparticles of pro-apoptotic and cathepsin B-cleavable peptide-conjugated doxorubicin for drug-resistant cancer therapy. Biomaterials 261, 120347 (2020).","journal-title":"Biomaterials"},{"issue":"1","key":"24027_CR22","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.apsb.2021.08.012","volume":"12","author":"S Fu","year":"2022","unstructured":"Fu, S. et al. Pure drug nano-assemblies: A facile carrier-free nanoplatform for efficient cancer therapy. Acta Pharm. Sin. B. 12(1), 92\u2013106 (2022).","journal-title":"Acta Pharm. Sinica B"},{"issue":"5","key":"24027_CR23","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1016\/j.nano.2018.04.009","volume":"14","author":"V Kushwah","year":"2018","unstructured":"Kushwah, V., Katiyar, S. S., Agrawal, A. K., Gupta, R. C. & Jain, S. Co-delivery of docetaxel and gemcitabine using pegylated self-assembled stealth nanoparticles for improved breast cancer therapy. Nanomedicine 14(5), 1629\u20131641 (2018).","journal-title":"Nanomedicine: Nanatechnol. Biology Med."},{"issue":"7","key":"24027_CR24","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1021\/mp500744m","volume":"12","author":"F Chen","year":"2015","unstructured":"Chen, F. et al. Synergistically enhanced therapeutic effect of a Carrier-Free HCPT\/DOX nanodrug on breast cancer cells through improved cellular drug accumulation. Mol. Pharm. 12(7), 2237\u20132244 (2015).","journal-title":"Mol. Pharm."},{"issue":"6","key":"24027_CR25","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1016\/j.biotechadv.2018.04.001","volume":"36","author":"S Mijatovi\u0107","year":"2018","unstructured":"Mijatovi\u0107, S. et al. Naturally occurring compounds in differentiation based therapy of cancer. Biotechnol. Adv. 36(6), 1622\u20131632 (2018).","journal-title":"Biotechnol. Adv."},{"issue":"8","key":"24027_CR26","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1002\/ptr.5631","volume":"30","author":"X Dong","year":"2016","unstructured":"Dong, X. et al. A review of its Pharmacology, toxicity and pharmacokinetics. Phytother. Res. 30(8), 1207\u20131218 (2016).","journal-title":"Phytother. Res."},{"issue":"2","key":"24027_CR27","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.canlet.2013.08.023","volume":"341","author":"D Shrimali","year":"2013","unstructured":"Shrimali, D. et al. Targeted abrogation of diverse signal transduction cascades by Emodin for the treatment of inflammatory disorders and cancer. Cancer Lett. 341(2), 139\u2013149 (2013).","journal-title":"Cancer Lett."},{"key":"24027_CR28","doi-asserted-by":"crossref","unstructured":"Correia da Silva, D., Valent\u00e3o, P. & Pereira, D. M. A survey of naturally occurring molecules as new Endoplasmic reticulum stress activators with selective anticancer activity. Cancers 15(1) (2022).","DOI":"10.3390\/cancers15010293"},{"key":"24027_CR29","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.2147\/DDDT.S196319","volume":"13","author":"S Chen","year":"2019","unstructured":"Chen, S., Zhang, Z. & Zhang, J. Emodin enhances antitumor effect of Paclitaxel on human non-small-cell lung cancer cells in vitro and in vivo. Drug. Des. Devel. Ther. 13, 1145\u20131153 (2019).","journal-title":"Drug. Des. Devel. Ther."},{"key":"24027_CR30","doi-asserted-by":"publisher","first-page":"47","DOI":"10.2147\/IJN.S282154","volume":"16","author":"W Wei","year":"2021","unstructured":"Wei, W. et al. Antitumor effects of Self-Assembling Peptide-Emodin in situ hydrogels in vitro and in vivo. Int. J. Nanomed. 16, 47\u201360 (2021).","journal-title":"Int. J. Nanomed."},{"key":"24027_CR31","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s12951-020-00679-2","volume":"18","author":"R Wang","year":"2020","unstructured":"Wang, R. et al. Synergistic Inhibition of metastatic breast cancer by dual-chemotherapy with excipient-free rhein\/DOX nanodispersions. J. Nanobiotechnol. 18, 116 (2020).","journal-title":"J. Nanobiotechnol."},{"key":"24027_CR32","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1186\/s12951-023-02157-x","volume":"21","author":"M Yuan","year":"2023","unstructured":"Yuan, M. et al. Shi, L. A carrier-free supramolecular nano-twin-drug for overcoming irinotecan-resistance and enhancing efficacy against colorectal cancer. J. Nanobiotechnol. 21, 393 (2023).","journal-title":"J. Nanobiotechnol."},{"issue":"7","key":"24027_CR33","doi-asserted-by":"publisher","first-page":"5858","DOI":"10.1021\/nn4010796","volume":"7","author":"X Duan","year":"2013","unstructured":"Duan, X. et al. Smart pH-sensitive and temporal-controlled polymeric micelles for effective combination therapy of doxorubicin and Disulfiram. ACS Nano. 7(7), 5858\u20135869 (2013).","journal-title":"ACS Nano"},{"key":"24027_CR34","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.biomaterials.2018.01.042","volume":"162","author":"J Zhu","year":"2018","unstructured":"Zhu, J. et al. Dual-responsive polyplexes with enhanced disassembly and endosomal escape for efficient delivery of SiRNA. Biomaterials 162, 47\u201359 (2018).","journal-title":"Biomaterials"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-24027-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-24027-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-24027-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T10:04:10Z","timestamp":1763805850000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-24027-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,17]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["24027"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-24027-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,17]]},"assertion":[{"value":"2 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"40205"}}